Other Species / Isoforms
  TBCB (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S31-p
SEKRYSRsLtIAEFK
0 8
TBCB (human) SEKRYSRsLtIAEFK S31-p
TBCB (mouse) SEKRYSRsLTIAEFK S31-p
TBCB (rat) SEKRYSRSLTIAEFK S31
T33-p
KRYSRsLtIAEFKCK
0 4
TBCB (human) KRYSRsLtIAEFKCK T33-p
TBCB (mouse) KRYSRsLTIAEFKCK T33
TBCB (rat) KRYSRSLTIAEFKCK T33
S47
KLELLVGSPASCMEL
0 1
TBCB (human) KLELLVGSPASCMEL S47
TBCB (mouse) KLELVVGsPAsCMEL S47-p
TBCB (rat) KLELVVGSPASCMEL S47
S50
LLVGSPASCMELELY
0 1
TBCB (human) LLVGSPASCMELELY S50
TBCB (mouse) LVVGsPAsCMELELY S50-p
TBCB (rat) LVVGSPASCMELELY S50
S65-p
GVDDKFYskLDQEDA
Upstream
Downstream
2 0
Effects on Biological Processes:
  • cytoskeletal reorganization
Kinase, in vitro:
  • PAK1 (human)
Putative in vivo kinases:
  • PAK1 (human)
Treatment
  • EGF
  • siRNA
  • SNP
TBCB (human) GVDDKFYskLDQEDA S65-p
TBCB (mouse) GADDKFYSKLDQEDA S65
TBCB (rat) GADDQFYSKLDQEDA S65
K66-ub
VDDKFYskLDQEDAL
0 1
TBCB (human) VDDKFYskLDQEDAL K66-ub
TBCB (mouse) ADDKFYSKLDQEDAL K66
TBCB (rat) ADDQFYSKLDQEDAL K66
S91-p
RIHVIDHsGARLGEy
0 1
TBCB (human) RIHVIDHsGARLGEy S91-p
TBCB (mouse) RIHVIDHSGVRLGEy S91
TBCB (rat) RIHVIDHSGVRLGEy S91
Y98-p
sGARLGEyEDVsRVE
Upstream
1 862
Treatment
  • ephrin_B1
  • ephrin_B2
  • erlotinib
  • PD173074
  • Su11274
  • U0126
TBCB (human) sGARLGEyEDVsRVE Y98-p
TBCB (mouse) SGVRLGEyEDVSkVE Y98-p
TBCB (rat) SGVRLGEyEDVSKVE Y98-p
S102-p
LGEyEDVsRVEkytI
0 14
TBCB (human) LGEyEDVsRVEkytI S102-p
TBCB (mouse) LGEyEDVSkVEKYEI S102
TBCB (rat) LGEyEDVSKVEKYEI S102
R103
GEyEDVsRVEkytIs
0 1
TBCB (human) GEyEDVsRVEkytIs R103
TBCB (mouse) GEyEDVSkVEKYEIs K103-ub
TBCB (rat) GEyEDVSKVEKYEIs K103
K106-ub
EDVsRVEkytIsQEA
Upstream
0 26
Treatment
  • MG132
TBCB (human) EDVsRVEkytIsQEA K106-ub
TBCB (mouse) EDVSkVEKYEIsPEA K106
TBCB (rat) EDVSKVEKYEIsPEA K106
Y107-p
DVsRVEkytIsQEAy
0 158
TBCB (human) DVsRVEkytIsQEAy Y107-p
TBCB (mouse) DVSkVEKYEIsPEAY Y107
TBCB (rat) DVSKVEKYEIsPEAY Y107
T108-p
VsRVEkytIsQEAyD
0 13
TBCB (human) VsRVEkytIsQEAyD T108-p
TBCB (mouse) VSkVEKYEIsPEAYE E108
TBCB (rat) VSKVEKYEIsPEAYE E108
S110-p
RVEkytIsQEAyDQR
Upstream
0 58
Treatment
  • ischemia
  • UV
TBCB (human) RVEkytIsQEAyDQR S110-p
TBCB (mouse) kVEKYEIsPEAYERR S110-p
TBCB (rat) KVEKYEIsPEAYERR S110-p
Y114-p
ytIsQEAyDQRQDtV
0 136
TBCB (human) ytIsQEAyDQRQDtV Y114-p
TBCB (mouse) YEIsPEAYERRQNTV Y114
TBCB (rat) YEIsPEAYERRQNTV Y114
T120-p
AyDQRQDtVRsFLKR
0 8
TBCB (human) AyDQRQDtVRsFLKR T120-p
TBCB (mouse) AYERRQNTVRSFMKR T120
TBCB (rat) AYERRQNTVRSFMKR T120
S123-p
QRQDtVRsFLKRsKL
0 1
TBCB (human) QRQDtVRsFLKRsKL S123-p
TBCB (mouse) RRQNTVRSFMKRSkL S123
TBCB (rat) RRQNTVRSFMKRSKL S123
S128-p
VRsFLKRsKLGRyNE
Upstream
Downstream
2 0
Effects on Biological Processes:
  • cytoskeletal reorganization
Kinase, in vitro:
  • PAK1 (human)
Putative in vivo kinases:
  • PAK1 (human)
Treatment
  • EGF
  • siRNA
  • SNP
TBCB (human) VRsFLKRsKLGRyNE S128-p
TBCB (mouse) VRSFMKRSkLGPYNE S128
TBCB (rat) VRSFMKRSKLGPYNE S128
K129
RsFLKRsKLGRyNEE
0 1
TBCB (human) RsFLKRsKLGRyNEE K129
TBCB (mouse) RSFMKRSkLGPYNEE K129-ub
TBCB (rat) RSFMKRSKLGPYNEE K129
Y133-p
KRsKLGRyNEEERAQ
0 4
TBCB (human) KRsKLGRyNEEERAQ Y133-p
TBCB (mouse) KRSkLGPYNEELRAQ Y133
TBCB (rat) KRSKLGPYNEELRAQ Y133
A150
AEAAQRLAEEkAQAS
0 1
TBCB (human) AEAAQRLAEEkAQAS A150
TBCB (mouse) AEAAQRLsEEkAQAS S150-p
TBCB (rat) AEAAQRLSEEEAQAS S150
K153-ac
AQRLAEEkAQASSIP
0 2
TBCB (human) AQRLAEEkAQASSIP K153-ac
TBCB (mouse) AQRLsEEKAQASAIS K153
TBCB (rat) AQRLSEEEAQASAIS E153
K153-ub
AQRLAEEkAQASSIP
0 23
TBCB (human) AQRLAEEkAQASSIP K153-ub
TBCB (mouse) AQRLsEEkAQASAIS K153-ub
TBCB (rat) AQRLSEEEAQASAIS E153
S173-p
EVRAAGQsPRRGTVM
0 1
TBCB (human) EVRAAGQsPRRGTVM S173-p
TBCB (mouse) EVRAPDHSLRRGTVM S173
TBCB (rat) EVRAPGQSLRRGTVM S173
K188-ub
YVGLTDFkPGYWIGV
0 2
TBCB (human) YVGLTDFkPGYWIGV K188-ub
TBCB (mouse) YVGLTDFKPGYWVGV K188
TBCB (rat) YVGLTDFKPGYWVGV K188
K203-ub
RYDEPLGkNDGSVNG
0 29
TBCB (human) RYDEPLGkNDGSVNG K203-ub
TBCB (mouse) RYDEPLGkNDGSVNG K203-ub
TBCB (rat) RYDEPLGKNDGSVNG K203
K211-ub
NDGSVNGkRYFECQA
0 2
TBCB (human) NDGSVNGkRYFECQA K211-ub
TBCB (mouse) NDGSVNGKRYFECQA K211
TBCB (rat) NDGSVNGKRYFECQA K211
K219-ac
RYFECQAkYGAFVKP
0 1
TBCB (human) RYFECQAkYGAFVKP K219-ac
TBCB (mouse) RYFECQAKYGAFVKP K219
TBCB (rat) RYFECQAKYGAFVKP K219
K219-ub
RYFECQAkYGAFVKP
0 2
TBCB (human) RYFECQAkYGAFVKP K219-ub
TBCB (mouse) RYFECQAKYGAFVKP K219
TBCB (rat) RYFECQAKYGAFVKP K219
Y239-p
GDFPEEDyGLDEI__
Upstream
0 108
Treatment
  • gefitinib
TBCB (human) GDFPEEDyGLDEI__ Y239-p
TBCB (mouse) GDFPEEDyGLDEM__ Y239-p
TBCB (rat) GDFPEEDYGLDEM__ Y239